ArticleAnnals of hematology2025
Genomic mutation profile and metabolic alterations in diffuse large B-cell lymphoma with abdominal bulky mass.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming.Journal of translational medicine · 2026Article
- Alterations in Gut Microbiota and Metabolic Profiles in Relapsed or Refractory Lymphoma.MicrobiologyOpen · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a tumor with significant clinical and genetic heterogeneity. DLBCL with bulky mass (≥ 7.5 cm) exhibits a negative prognostic impact. Due to the low incidence and the lack of relevant studies, the drivers and characteristic genetic mutations of DLBCL with abdominal bulky mass (DLBCL-AB) remain unclear. To explore individualized treatment strategies by analyzing genomic mutation profile and characteristic biological alterations in DLBCL-AB may help to optimize patients' prognosis. Next-generation sequencing of tumor tissues from 39 patients (29 with DLBCL-AB and 10 with common DLBCL) was performed to screen mutation profiles. Three platforms, gas chromatography-mass spectrometry (GC-MS), high-resolution liquid chromatography-mass spectrometry (LC-MS polar), and high-resolution liquid chromatography-mass spectrometry (LC-MS lipid), were used to analyze the metabolic differences in the plasma samples and screen the profiles of altered metabolic substances. Bioinformatic analysis was used to explore the correlation between key genes and characteristic metabolic changes. CD58, TP53, CCND3 and CXCR4 were potential driver genes of DLBCL-AB. ETV6 and KDM5A mutations were independent risk factors for DLBCL-AB prognosis. In addition, DLBCL-AB had unique features in the pathways of ketone body synthesis and degradation, galactose metabolism, linoleic acid metabolism, aminoacyl-tRNA biosynthesis, and exotic amino acid biosynthesis. The results of bioinformatic analysis indicated that ETV6 may be the pivotal gene involved in regulating DLBCL-AB galactose metabolism and linoleic acid metabolism and affecting patient prognosis. This study comprehensively described the changes in the genetic features and metabolic characteristics of DLBCL-AB, thereby providing a theoretical basis for the precision treatment of patients with this high-risk lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.